Navigation Links
First generation antipsychotic drugs as effective as newer ones in some children
Date:9/14/2008

CHAPEL HILL Nearly every child who receives an antipsychotic medicine is first prescribed one of the second-generation, or atypical drugs, such as olanzapine and risperidone. However, there has never been evidence that these drugs are more effective than the older, first-generation medications.

Now a study from the University of North Carolina at Chapel Hill School of Medicine suggests that molindone, a first-generation drug, is as effective as the newer ones and should be used as a first line of therapy in some children with schizophrenia or schizoaffective disorder.

People thought the second-generation drugs were superior because they had no side effects. We found that molindone works as well as newer drugs, and in some cases its safer, said Lin Sikich, M.D., associate professor in the department of psychiatry at UNC and lead author of the study, titled the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.

The guidelines are going to have to be rewritten because of this study, Sikich said. A report of the study is published Monday in the Sept. 15, 2008 edition of the American Journal of Psychiatry. Co-author Jeffrey Lieberman, M.D., led the earlier CATIE trial at UNC, a landmark study that compared antipsychotic medications in adults. Lieberman is now at Columbia University Medical Center.

The study is the largest head-to-head trial comparing the newer drugs, which became available in the 1990s, to the older ones, which have been around since the 1950s.

Between 2002 and 2006 the study randomly assigned 119 people aged 8 to 19 years to receive molindone, olanzapine or risperidone over an eight-week period at four sites: UNC; McLean Hospital and Cambridge Health Alliance at Harvard Medical School; Seattle Childrens Hospital and the University of Washington; and Case Western Reserve University.

A decline in symptoms was similar across the three medications. But the drugs caused very different types of side effects, Sikich said. Both olanzapine and risperidone were associated with significant weight gain and could put young patients at risk of developing heart disease and diabetes. In fact, the National Institute of Mental Health, which sponsored the study, halted recruitment into the olanzapine arm of the study because of the weight gain problem and the resulting increase in cholesterol and glucose levels.

Olanzapine should not be a first-line therapy in adolescents, Sikich said.

Both the older typical antipsychotics and newer atypical ones block dopamine receptors in the brain, but the newer drugs also interact with serotonin receptors and cause fewer muscle side effects, including stiffness, muscle cramps, restlessness and involuntary movements. With some older drugs, the involuntary movements can lead to permanent physical disabilities.

There were more reported cases of restlessness with molindone treatment than with either of the two newer treatments. Participants treated with molindone were also required to receive another drug, benztropine, to decrease muscle cramps and stiffness.

Brandon Constantineau, 18, of Wilmington, N.C., enrolled in the TEOSS study about four years ago. He was initially prescribed olanzapine but quickly began gaining weight, ultimately adding more than 45 pounds over 36 weeks. He was switched to molindone and gained about 8 pounds over the next 31 weeks and saw improvements similar to those with olanzapine. But, probably as a result of being on olanzapine, Sikich said, Brandon developed fatty liver disease and was ultimately prescribed two other medications.

Brandons case also highlights two other points Sikich makes in the study: the benefits of proper diagnosis and the need for more effective medications.

He was treated when he was very young, about 3, for ADHD, said Brandons father, Richard Constantineau. But medications and other therapies didnt help, and Brandon grew violent.

At the point when we went to see Dr. Sikich, when Brandon was 14, I was getting phone calls from the school because he was making threats against teachers, said Brandons mother, Darlene Wilson. This coincided with violent threats against his parents and, Brandon said, at one point in time I thought I was seeing angels with halos and wings, like in the Bible.

A psychiatrist Brandon had been seeing was not helpful, Wilson said, so a pediatrician referred them to Sikich.

Late diagnosis is a common problem with many children who develop early onset schizophrenia or schizoaffective disorder, and the diseases usually develop more severely when they begin in childhood, Sikich said.

Brandon is now doing well on an even newer drug, ziprasidone. But in the TEOSS trial only half of all of the participants responded to any medication.

Medications make a vast difference in peoples lives, but we need better treatment options, Sikich said. The trial will next compare outcomes after a one-year course of treatment.

Brandon and his family appreciate first-hand the challenges and advances.

Its working well for him and we need to enjoy the good times, because its not always good times, Wilson said. We just have to enjoy what we have right now.


'/>"/>

Contact: Clinton Colmenares
ccolmena@unch.unc.edu
919-966-8757
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Vasculitis Foundation Integrates Education, Outreach and Technology in First-Ever Webinar on Potentially Life-Threatening Disease
2. The Cancer Genome Atlas reports first results, Johns Hopkins Kimmel Cancer Center collaborates
3. The Decline of Males, Why They Die First; at White Plains Hospital September 17
4. Kids Fever Time Cut Using Ibuprofen First
5. Ethiopia First Nation to Sign National Health Partnership Compact
6. Cogdell Spencer Announces First Synergy Project in Pensacola, Florida
7. Australian over-50s walk away memory problems in world-first trial
8. The first autism disease genes
9. Chrigu Wins Grand Prize at First Ever International Documentary Film Festival on Cancer
10. Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania
11. San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... ... tick-borne diseases through research, education and awareness, today announced the appointment of Timothy ... and microbiologist, Dr. Sellati has more than 20 years of research experience with ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      ... things wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing ... in compliance with FDA rules. , The FDA has issued two draft guidances ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create ... back to the community. For over 37 years, they have operated with their mission ... plumbing in San Diego. They were chosen as the Best San Diego plumber ...
(Date:9/21/2017)... Southborough, Mass. (PRWEB) , ... September 21, 2017 , ... ... for children with autism, announced today the election of Yie-Hsin Hung to the Board ... Yie-Hsin Hung join our Board of Directors. Ms. Hung is an invaluable addition to ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: